Becton Dickinson India
- Company typePublic
- Founded1897
- HeadquartersGurugram, India
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
Becton Dickinson India firmographics
Firmographics- Name
- Becton Dickinson India
- Legal name
- Becton, Dickinson and Company
- Website
- https://bd.com
- Company type
- Public
- Founded year
- 1897
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Ownership category
- akta.pro rank
Becton Dickinson India industry classification
Industry- Product category
- Medical Devices and Diagnostic Systems
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), In-Vitro Diagnostic Substance Manufacturing (325413), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
- akta.pro primary industry
- IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)
- akta.pro secondary industries
- Surgical Stapling, Suturing & Hemostasis (Staplers, Clips, Sealants, Tourniquets) (HLAHADAL), Diagnostic & Laboratory Packaging (Specimen Containers, Transport Tubes) (IMALAIAF), Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules) (IMALAIAA)
Keywords
Where Becton Dickinson India is headquartered
LocationHeadquarters
- HQ city
- Gurugram
- HQ country
- India
- HQ region
- Asia
Offices4 records
Markets served
Becton Dickinson India business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations
Revenue model
- Medical Devices and Consumables: Sale of medical supplies and devices including syringes, needles, catheters, vascular access products, surgical instruments, and diagnostic consumables. Generates recurring revenue from consumables used in healthcare settings.
- Medication Management Systems: BD Pyxis medication dispensing technologies and BD Alaris Infusion Systems with AI-powered analytics. Systems typically sold with ongoing consumable revenue.
- Diagnostic Systems and Reagents: Blood culture systems (BACTEC), molecular diagnostics (BD MAX), microbiology automation (BD Kiestra, BD Phoenix), flow cytometry (FACSLyric), and associated reagents and consumables.
- Biologic Drug Delivery: Prefilled injectable devices and wearable injectors for GLP-1 and other biologic drugs. Growing segment surpassing $1 billion in annual revenue.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Multi-year contract | Medical devices and consumables - pricing varies by product category and volume |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels8 records
Becton Dickinson India product offering
Product offeringCore offering
Becton Dickinson India develops, manufactures, and sells medical devices, instrument systems, and reagents across three segments: BD Medical (medication delivery, vascular access, surgery, urology, and hazardous drug safety), BD Life Sciences (specimen collection, diagnostic systems, clinical microbiology, molecular diagnostics, and lab automation), and BD Interventional (vascular and oncology). The portfolio spans more than 8,299 products including BD Pyxis medication management, BD Alaris infusion systems, BD BACTEC blood culture, BD MAX molecular diagnostics, BD Kiestra lab automation, BD ChloraPrep surgical prep, hypodermic needles and syringes, vascular access devices, and surgical meshes, sold primarily to hospitals, health systems, ambulatory surgery centers, laboratories, and pharmacies.
Product overview
BD (Becton, Dickinson and Company) is a global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. The company operates across three main segments: BD Medical (medication delivery, vascular access, surgery, urology, acute urology, and hazardous drug safety), BD Life Sciences (specimen collection, diagnostic accuracy, clinical microbiology, molecular diagnostics, and lab automation), and BD Interventional (vascular access management, peripheral intervention, and oncology). The portfolio includes integrated platforms like BD Pyxis Pro for medication management, BD Alaris Infusion System, and BD Incada Connected Care Platform, alongside specialized products such as BD BACTEC blood culture systems, BD Kiestra lab automation, BD FACSLyric flow cytometry, BD ChloraPrep surgical prep, PureWick external catheters, and BD PhaSeal closed-system drug transfer devices. BD serves healthcare institutions, laboratories, and clinicians across acute care, alternate sites, and home healthcare settings worldwide.
Differentiator
Problem solved
Functional benefit
Brands
- BD Alaris: Infusion systems and medication management technology
- BD Pyxis
- BD Vacutainer
- BD BACTEC
- PureWick
- BD ChloraPrep
- BD Libertas
- HemoSphere
- Phasix
- Venovo
- CentroVena One
- Elyra
Products and services
- BD Pyxis Pro Dispensing Solution
Quantifiable outcome
- CentroVena One reduces procedural steps by 30% and insertion time by 50% compared to traditional central line placement
- +6 more outcomes
Companies that use Becton Dickinson India
Customer profileNamed customers3 records
Segments6 records
Ideal customer profiles5 records
Becton Dickinson India technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability8 records
Feature8 records
Becton Dickinson India partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Wellstar Health SystemcoreStrategic partnership to deploy AI-powered medication management technology across Wellstar's Georgia-based hospitals and care facilities. Combines BD Pyxis Pro medication dispensing technologies and BD Alaris Infusion Systems powered by BD Incada AI analytics. Provides enterprise-wide medication inventory visibility, real-time insights, and streamlined clinical workflows through EMR interoperability. Wellstar joins BD's Strategic Development Council to shape future medication management innovation.
- Quvara MedicalminorTransfer of BD's Swindon, UK production facility to Quvara Medical. Facility continues producing BD products under partnership agreement while Quvara builds independent operations. Transfer of 300+ employees.
- Envetec Sustainable TechnologiesminorClosed-loop recycling feasibility study partnership to advance recycling of healthcare plastics, supporting BD's sustainability goals and circular economy initiatives in pharmaceutical packaging.
- Waters CorporationcoreReverse Morris Trust transaction combining BD's Biosciences & Diagnostic Solutions business with Waters Corporation for approximately $17.5 billion (at ~19x EBITDA multiple). Generated $4 billion in cash for BD, deployed toward $2B share buybacks and $2B debt repayment. Transformed BD into a pure-play medical technology company.
- BactiguardcoreGlobal licensing partnership for infection-prevention catheter technologies. Bactiguard's noble metal alloy coating technology licensed for use on BD's Foley catheters and other urology products. FDA 510(k) cleared products include Bardex I.C. Foley Catheter with Bactiguard coating shown to lower CAUTI occurrence.
- Edwards Lifesciences (Critical Care Product Group)coreAcquisition of Edwards Lifesciences' Critical Care product group for advanced hemodynamic monitoring technologies. Enriched BD's portfolio with AI-powered monitoring technologies including ForeSight IQ tissue oximetry sensors and Swan-Ganz pulmonary artery catheters.
- PreAnalytiX GmbH and QIAGENminorStrategic alliance to develop standardized urine liquid biopsy solution for non-invasive cell-free DNA analysis. Combines expertise in specimen collection, nucleic acid preservation, and molecular diagnostics.
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
Becton Dickinson India competitors and assessment
Company assessmentDirect peers
- Becton, Dickinson and Company (Global Parent): BD's global parent entity headquartered in Franklin Lakes, NJ. Operates the same medical device, diagnostics, and medication management portfolio across all geographies; the Indian operations are a regional subset of this parent and share product lines, brands, and management.
- B. Braun: German medical device and pharmaceutical company with overlapping portfolios in IV therapy, syringes, infusion pumps, surgical instruments, and urology. Directly competes with BD in hospital consumables and infusion systems globally, including India.
- Baxter International: Global medical products company with overlapping product lines in IV infusion pumps, IV sets, surgical products, and patient monitoring. Competes directly with BD in medication delivery and surgical solutions across global hospital channels.
- ICU Medical: Specialist in IV infusion systems, medical connectors, and closed-system transfer devices. Direct competitor to BD's Alaris infusion platform and hazardous drug safety portfolio (PhaSeal), competing head-to-head on hospital infusion contracts.
- Smith+Nephew: Global medical technology company with strong positions in advanced wound management, surgical devices, and orthopedics. Directly competes with BD's surgical solutions portfolio and hernia repair products in the surgical suite.
- Teleflex: Specializes in single-use medical devices for critical care and surgical applications including vascular access, anesthesia, and urology. Closely comparable to BD's vascular access and acute care segments with similar hospital-channel distribution.
- Cardinal Health: Major medical supply distributor and medical product manufacturer. Competes with BD both as a distribution channel for hospital products and increasingly through its own manufactured consumables and medical devices portfolio.
Broad incumbents
- Medtronic: Largest diversified medical device company worldwide. Overlaps with BD in vascular access, surgical instruments, patient monitoring, and diabetes. While broader in therapeutic areas, Medtronic competes with BD on procedural efficiency and hospital contracts.
- Abbott Laboratories: Diversified global healthcare company with major diagnostics and medical device segments. Competes with BD's diagnostics franchise (especially post-Waters spin-off) and shares the connected health/patient monitoring opportunity.
- Thermo Fisher Scientific: Largest life sciences tools and diagnostics company globally. Overlaps with BD in clinical diagnostics, microbiology automation, and specimen collection, particularly relevant as BD divests its Biosciences and Diagnostic Solutions business.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Becton Dickinson India social profiles
Digital presenceBecton Dickinson India compliance and trust
Trust signalCompliance7 records
Becton Dickinson India financial estimates
Financial estimateRevenue estimate
Valuation estimate
Becton Dickinson India leadership team
Management profileNumber of profiles
Profiles19 records
Becton Dickinson India subsidiaries and ownership
Company hierarchySubsidiaries5 records
Becton Dickinson India funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Becton Dickinson India M&A and investment
M&A and investmentM&A32 records
Investments13 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Becton Dickinson India
What does Becton Dickinson India do?
Becton Dickinson India develops, manufactures, and sells medical devices, instrument systems, and reagents across three segments: BD Medical (medication delivery, vascular access, surgery, urology, and hazardous drug safety), BD Life Sciences (specimen collection, diagnostic systems, clinical microbiology, molecular diagnostics, and lab automation), and BD Interventional (vascular and oncology). The portfolio spans more than 8,299 products including BD Pyxis medication management, BD Alaris infusion systems, BD BACTEC blood culture, BD MAX molecular diagnostics, BD Kiestra lab automation, BD ChloraPrep surgical prep, hypodermic needles and syringes, vascular access devices, and surgical meshes, sold primarily to hospitals, health systems, ambulatory surgery centers, laboratories, and pharmacies.
Is Becton Dickinson India a public or private company?
Becton Dickinson India is a public company. It is classified as public and is currently operating.
When was Becton Dickinson India founded?
Becton Dickinson India was founded in 1897. It employs 5,001 to 10,000 people.
Where is Becton Dickinson India based?
Becton Dickinson India is headquartered in Gurugram, India, in the Asia region.
How does Becton Dickinson India make money?
Four revenue lines are on record. Medical Devices and Consumables are the primary driver. The others are medication Management Systems, diagnostic Systems and Reagents and biologic Drug Delivery.
Who are Becton Dickinson India's main competitors?
Direct peers on record are Becton, Dickinson and Company (Global Parent), B. Braun, Baxter International, ICU Medical, Smith+Nephew, Teleflex and Cardinal Health. Broad incumbents are Medtronic, Abbott Laboratories and Thermo Fisher Scientific.
Does Becton Dickinson India have an API?
No public API is recorded for Becton Dickinson India.
What industry is Becton Dickinson India in?
Becton Dickinson India's product category is Medical Devices and Diagnostic Systems. Its primary akta.pro industry code is HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument), with a secondary code of HLAHADAL, Surgical Stapling, Suturing & Hemostasis (Staplers, Clips, Sealants, Tourniquets). Its NAICS code is 339112 and its SIC code is 3841.